We have previously shown that hyperthyroidism is detrimental for liver fibrosis and in this study we have investigated the mechanisms regulating triiodothyronine (T3) and L-thyroxine (T4) activation of hepatic stellate cells (HSC). Expression of a-smooth muscle actin (aSMA) and p75 neurotrophin receptor (p75NTR) was determined by western blot analyses and transient transfection of the promoters. Rho activation was assayed using a pull-down assay and by ELISA. Expression of thyroid hormone receptor a1 decreases, whereas T4 receptor integrin aVb3 increases, with transdifferentiation of HSC to myofibroblasts. T3 and T4 enhance HSC activation, without affecting proliferation or phosphorylation of mitogen-activated protein kinase, signal transducer and activator of transcription 3 or Akt. Addition of 10 À7 M T3 or T4 to thyroid hormone-depleted serum induces a twofold increase in activation marker aSMA, as well as upregulation of p75NTR protein levels. Both hormones enhance transcription of aSMA and p75NTR. We report a novel signaling pathway for thyroid hormones, activation of Rho. T4 induces activation of Rho acting through avb3 integrin, and the activation is abolished by the T4 antagonist, tetraiodothyroacetic acid, by peptide RGD and by a function-blocking antibody to integrin b3. T3 and T4 increase phosphorylation of non-muscle myosin light chain II, a downstream signal to Rho/Rho-kinase activation. T3 also induces expression of tumor necrosis factor-a. In vivo, administration of T3 or T4 together with thioacetamide (TAA) enhances fibrosis after 3 weeks, compared with the TAA-treated group, accompanied by increased aSMA in T3-and T4-treated groups, and of p75NTR in T4-treated rats. Thyroid hormones enhance activation of HSC through increased p75NTR and aSMA expression and activation of Rho, therefore accelerating development of liver fibrosis.
Chronic liver injury caused by viral hepatitis, alcohol and drugs results at first in fibrosis, and if the injury persists, leads to liver cirrhosis. The main source of the scar tissue during liver fibrosis and cirrhosis is the hepatic stellate cells (HSC).
1,2 On activation, HSC undergo proliferation and differentiation, 1,2 becoming myofibroblast-like a-smooth muscle actin (aSMA)-positive cells that produce extracellular matrix proteins, particularly type I collagen. 1, 2 We have previously shown that hypothyroidism, induced chemically or surgically, prevents liver cirrhosis in a thioacetamide (TAA) rat model of fibrosis 3 and recent studies show that hypothyroidism also helps regression of established liver cirrhosis. 4 Thyroid hormones, triiodothyronine (T3) and L-thyroxine (T4) have central roles in growth, differentiation and metabolism, acting mainly through transcriptional regulation of target genes. 5 The main circulating thyroid hormone, T4, is deiodinated inside cells by various deiodinases and becomes T3. T3 enters the nucleus and binds to nuclear thyroid hormone receptors, bound to target genes containing thyroid response elements (TRE). 5 The two major receptor isoforms, thyroid hormone receptor a1 and b1 (TRa1 and TRb1), are encoded by two separate genes and have tissue-specific distribution, with liver expressing mainly TRb1, and heart expressing TRa1. 5 We have shown that an immortalized hepatic stellate cell line, HSC-T6, expresses TRa1, but not TRb1, whereas primary hepatocytes express both. 6 Recently, T4 was shown to bind and signal through cell-surface integrin avb3, 7 inducing proliferation in various cells expressing high levels of avb3. 8 The T4-induced signal transduction pathway includes phosphorylation of signal transducer and activator of transcription 1 (STAT1), STAT3 and mitogen-activated protein kinase (MAPK) and their translocation to the nucleus. 8 Moreover, silencing of integrin av b3 using siRNA, or blocking the signaling of this receptor, induces HSC apoptosis. 9 Recent studies have shed light on the function of p75 neurotrophin receptor (p75NTR) in HSC activation and show that in p75NTRÀ/À mice, HSC are unable to become activated and to express aSMA. 10 Interestingly, p75NTR is effective in activating HSC in the absence of its ligand, nerve growth factor (NGF), signaling through activation of guanosine triphosphatase Rho. 10 Activation of members of Rho GTPase is reported to be crucial for HSC activation, as Rho inhibition attenuates liver fibrosis in several in vivo models. 11, 12 Quiescent HSC do not express p75NTR, but start expressing it on activation, 13 whereas hepatocytes do not express this receptor. 14 Recent studies show that hyperthyroidism induces expression of p75NTR in normal liver. 15 On the basis of our previous studies and on studies describing the role of p75NTR in HSC activation, we have investigated the connection between thyroid hormones and activation of primary HSC in vivo and in vitro, and delineated the mechanisms involved, including transcription of p75NTR and Rho activation, leading to increased expression of aSMA.
MATERIALS AND METHODS Isolation of Primary Rat HSC
Livers of female rat Wistar (retired breeders) were perfused with Gey's balanced salt solution (GBSS), then GBSS with 100 mg collagenase (Worthington Biochemical Corporation, NJ, USA) and 130 mg pronase (Roche Diagnostics, Mannheim, Germany). The digested liver was minced and incubated with 100 ml of GBSS with 25 mg pronase, 25 mg collagenase, 20 mg/ml DNAse I for 30 min at 371C with 200 r.p.m. shaking. HSC were isolated on a 17.5% Nycodenz gradient centrifuged at 1400 g for 20 min. 9 Primary HSC Culture Conditions Cells were cultured in DMEM with 10% fetal calf serum (FCS) and 100 mg/ml penicillin/streptomycin. To test effect of T3, we grown the cells for 24 h in serum-free DMEM with 10 À7 M T3 (Sigma, St Louis, MI, USA). For other experiments, cells were grown in thyroid hormone-depleted serum medium (TDS), consisting of DMEM supplemented with 10% TDS. Depletion of T3 and T4 was obtained by overnight incubation of 2 g activated charcoal per 100 ml serum at 41C, followed by centrifugation and filtration. 16, 17 Proliferation Assays Proliferation was by cell counting (using a Coulter counter), by a proliferation kit EZ4U based on formation of tetrazolium salts (Biomedica Medizinprodukte, Vienna, Austria) and by BrdU incorporation (Exalpha Biologicals Inc., Watertown, MA, USA).
Western Blots
Equal amounts of total protein were separated by SDS-PAGE and blotted onto Hybond C extra. Blots were incubated with antibodies for TRa1 and TRb1 (Affinity Bioreagents, Golden, CO, USA), av, aSMA, PDGF receptor b, pMAPK (erk1/erk2), erk2, akt 1/2, STAT3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p75NTR (Upstate, Lake Placid, NY, USA), pSTAT3, pAkt and p-non-muscle myosin light chain II (pMLC; Cell Signaling Technology, Danvers, MA, USA), then incubated with horseradish-peroxidase-conjugated secondary antibody and detected by chemiluminescence. Expression was normalized to glyceraldehydes-3-phosphate dehydrogenase (GAPDH) or b-actin.
Immunohistochemistry
Hepatic stellate cells were washed with PBS and fixed in methanol: acetone (1:1) for 10 min at À201C. Cells were blocked for 30 min in PBS with 10% FCS, incubated for 1 h with aSMA antibodies (1:100; Santa Cruz Biotechnology), washed and incubated with secondary anti mouse-Cy3 (Jackson Immunoresearch Laboratories, Bar Harbor, ME, USA).
Oil Red O Staining
Hepatic stellate cells were cultured for 1, 2, 4, 5 and 7 days in TDS with or without 10 À7 M T3. Cells were fixed for 30 min in 10% formaldehyde and stained for 1 h with a 0.25% Oil Red O (Sigma) solution in propylene glycol.
Rho Activation Assays
Activated Rho was detected using a pull-down assay or an ELISA-based assay (Cytoskeleton, Denver, CO, USA). For the pull-down assay, 2, or 3 days and 5 days cultures of HSC were kept for 48 h in serum-free DMEM. Cells were pretreated for 30 min with 20 ml of a function-blocking antibody to b3 integrin (BioLegend, San Diego, CA, USA; clone 2C9.G2) or 500 nM RGD (arginine-glycine-aspartate) or 100 nM tetraiodothyroacetic acid (tetrac; Sigma), then T4 (10 À7 M) or T3 (10 À7 M) were added for 15 or 30 min and cells were scraped in a Mg 2 þ lysis buffer. Equal amounts of protein were incubated with rhotekin-agarose beads for 45 min at 41C, beads were washed and Rho-GTP bound to the beads was separated by gel electrophoresis, blotted and membranes were incubated with an Rho monoclonal antibody (Upstate). For the active RhoA ELISA, 5-day HSC were kept for 48 h in serum-free DMEM, then treated for 15 min with 10 À7 M T3 or T4 and 100 nM tetrac. Cell lysates were assayed according to the manufacturer's instructions.
Transient Transfections and Reporter Gene Assays
The plasmid containing the À764 bp aSMA promoterluciferase was from Dr S Phan (University of Michigan, MI, USA). The plasmids containing the À3724/ þ 13 human p75NTR promoter-luciferase and a shorter promoter region, À207/ þ 13, were from Dr P. Barker (McGill University, Montreal, Canada).
Hepatic stellate cells were transfected with 2 mg of the promoter of interest and 0.3 mg b-galactosidase expression vector with Gene Jammer reagent (Stratagene, La Jolla, CA, USA) and treated for 24 h in OptiMEM (Gibco-BRL) with 10 À7 M T3 and T4, 2.5 nM thyroid hormone receptor antagonist 1-850 (Calbiochem, Darmstadt, Germany), 10 mM Rho-kinase (ROCK) inhibitor Y-27632 (AG Scientific, San Diego, CA, USA) and 100 nM tetrac. Luciferase activity was determined using the Luciferase Assay Kit (Applied Biosystems, Bedford, MA, USA) and was normalized to b-gal activity.
RT-PCR for Cytokines
Total RNA extracted using an EZ-RNA kit (Biological Industries, Bet Haemek, Israel) was DNAse-treated and reverse-transcribed. The cDNAs were used for PCR, using the following primers: tumor necrosis factor-a (TNFa): 
0 . The PCR reaction contained 2 ml of cDNA reaction, 0.4 mM of each primer, 200 mM dNTP, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.1 mM MgCl 2 , 0.01% gelatin, 2.5 U RED TaqDNA polymerase (Sigma). After denaturation for 10 min at 941C, the PCR was started using 32 cycles at 941C for 50 s, 601C for 50 s and 721C for 50 s, with a final 5 min elongation step at 721C.
In Vivo Induction of Early Fibrosis and Hyperthyroidism
Male Wistar rats (300 g) were injected i.p. with 150 mg/Kg body weight TAA twice a week for 3 weeks. The groups of animals were: (1) control group receiving TAA (n ¼ 5); (2) TAA and T3 10 mg per rat injected s.c. five times a week (n ¼ 6); (3) TAA and T4 (Eltroxin) in the drinking water (10 mg/l) (n ¼ 6).
Statistical Analysis
Results are presented as fold inductions compared to control values considered 100% and are averages þ s.d. of at least three separate experiments. Statistical significance was assessed using an unpaired Student's t-test with P-value o0.05 considered significant.
RESULTS

Expression of TRa1 Decreases and av Increases with HSC Transdifferentiation into Myofibroblasts
Primary HSC undergo spontaneous, time-dependent activation in culture, with 2-to 4-day cultures considered quiescent, 7-day cultures becoming activated and 14-day cultured considered fully activated. We were interested to assess expression of T3 nuclear receptor TRa1, as well as expression of the newly described T4 receptor integrinavb3, as a function of HSC activation. TRa1 expression in primary cultures of HSC has been assessed using TRa1-specific antibodies (not cross-reactive with TRa2 or TRb1). Expression of TRa1 is high in 4-day (quiescent) and 7-day (activated) HSC, and dramatically decreases to only 30% in 14-day myofibroblasts (Figure 1a We have tested whether in vivo activation of HSC also causes TRa1 reduction. Activation of HSC in vivo was obtained by 3 weeks injection of TAA, then HSC were isolated and tested for expression of TRa1 after 4, 7 and 14 days in culture. TRa1 is strongly reduced in HSC from TAA-treated rats compared with expression of TRa1 in 4-day quiescent HSC from normal rats ( Figure 1c ).
Thyroid Hormones do not Affect HSC Proliferation T4 has been shown to induce proliferation of various cell types acting through integrin avb3. 8 The effect of T3 or T4 on proliferation of 7 and 14-day HSC has been determined by cell counting, by a proliferation kit based on formation of tetrazolium salts and by BrdU incorporation. T3 and T4 have no effect on proliferation tested by any of these methods (Figure 2a-c) .
Thyroid Hormones Induce Activation of HSC and Increase Expression of aSMA Because we have not observed effects of thyroid hormones on HSC proliferation, we have determined effects of these hormones on HSC activation. Spontaneous activation of HSC requires serum and is time dependent, so we needed to use serum for the duration of activation of HSC in culture, but use serum without thyroid hormones. Therefore, we have determined activation of HSC in the absence or presence of thyroid hormones using TDS. 16, 17 Both 4-day (not shown) and 7-day cultures of HSC grown in TDS show more aSMA-positive cells in TDS þ T3 and TDS þ T4 (Figure 3a ). With activation, HSC lose their retinoic acid granules, so this is another marker of HSC activation. Most HSC after 4 days in culture still show retinoic acid granules determined by Oil Red staining in both TDS and TDS þ T3 (Figure 3b ). To quantitate expression of aSMA, we performed western blot analyses of HSC cultured for 14 days in TDS, with or without 10 À7 M T3 and T4. Presence of T3 or T4 causes a twofold, statistically significant increase in the levels of aSMA protein, compared with TDS alone (Figure 3c and d) . The same effects are observed in 7-day cultures (not shown).
We have next investigated whether T3 and T4 induction of aSMa is transcriptionally mediated, as the aSMA promoter contains a TRE at À173/À149 bp and T3 induces aSMA transcription in cardiomyocytes. 17, 18 T3 addition to 7-day cultures of HSC induces a modest (20%), but statistically significant increase in transcription (Figure 3e ), which is abolished in the presence of 2.5 nM of the thyroid hormone receptor antagonist 1-850 (Figure 3e ). Moreover, aSMA transcription is known to be induced by Rho/ROCK signaling and the presence of 10 mM of ROCK inhibitor Y-27632 reduces transcription of aSMA by itself, as expected, but also abolishes T3 induction of aSMA transcription, indicating that T3 upregulation of aSMA transcription requires Rho/ ROCK signaling (Figure 3e ).
Thyroid Hormones Induce Expression of P75NTR
We have examined other possible mechanisms responsible for HSC activation by thyroid hormones. A receptor crucial for differentiation of HSC, p75NTR, 10 is upregulated in the livers Thyroid hormones induce HSC activation I Zvibel et al of hyperthyroid rats, following injection of T3 for 10 days. 15 We have therefore assessed the effect of T3 on the expression of p75NTR in HSC. Expression of p75NTR is low in 7-day HSC cultures grown in TDS (Figure 4a) , and is induced twoand threefold, respectively, in the presence of 10 À7 M T3 and T4 in 14-day cultures, as shown by western blot (Figure 4a and b) and by RT-PCR (Figure 4c and d) .
We have next determined whether T3 and T4 affected transcription of p75NTR, by transfecting vectors containing the luciferase reporter gene under the control of the proximal p75NTR promoter in 7-day HSC. We observed that 10 À7 M T3 and T4 enhance 1.4-and 1.7-fold, respectively, transcription of the full-length p75NTR promoter, À3724/ þ 13 bp and both hormones cause a twofold increase in the transcription of the shorter fragment, À207/ þ 13 bp (Figure 4e) . Moreover, both T3 antagonist 1-850 and T4 inhibitor tetrac abolish the transcriptional effect of T3 and T4 on the full-length p75NTR promoter (Figure 4f ).
T3 and T4 Signal through Rho Activation in HSC
We have next studied signaling mechanisms induced by thyroid hormones, which can explain their effects on activation of HSC. Several signal transduction pathways have been shown for thyroid hormones: T4, through integrin avb3, induces phosphorylation of MAPK and STAT3, 8 whereas T3, in addition to signaling through nuclear receptors TRa1 and TRb1, triggers association of TRa1 with the p85a subunit of phosphatidyl-inositol-3-kinase (PI3K), leading to Akt phosphorylation. 19 Treatment of 7-day cultures of HSC with 10 À7 M T3 or T4 for 30 min has no effect on phosphorylation of MAPK, Akt or STAT3 (Figure 5a ). 
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One of the known signals regulating activation of HSC is Rho activation, 10 and p75NTR has been shown to induce Rho activation in the absence of its ligand NGF. 10, 20 We assume that T3 and T4 may enhance Rho activation either through increased expression of p75NTR, or may directly induce Rho activation. Rho activation has first been tested by pull-down assay with Rhotekin agarose beads. Both T3 and T4 strongly induce Rho activation in both 4-and 7-day HSC, and Rho activation by T4 is abolished by T4 antagonist, tetrac (Figure 5b) . Pretreatment of cells with a functionblocking antibody to integrin b3 or with RGD inhibits T4, but not T3, activation of Rho (Figure 5c ). RhoA activation is also shown using ELISA. Both T3 and T4 activate RhoA in a dose-dependent manner after 15 min treatment, with a T4 dose of 10 À8 M sufficient for inducing RhoA activation (Figure 5d ).
The effects of T3 and T4 have next been assayed on the downstream signaling of Rho and ROCK activation, which consists of phosphorylation of pMLC. We have determined effects of T3 and T4 in 5-day cultures of HSC and have observed that T4 induces phosphorylation of MLC after 30 min, whereas T3 maximal effect is after 30 min. Tetrac abolishes the effect of both hormones (Figure 5e ).
T3 Increases Expression of TNFa
Activated HSC are known to express many inflammatory and profibrotic cytokines. We have determined mRNA for various cytokines in HSC cultured in TDS, with or without 10 À7 M T3, for 4, 7 and 14 days. There is a dramatic increase in SDF-1a expression during HSC activation, with strong SDF-1a expression in 14-day cultures (Figure 6a ). T3 increases expression of TNFa and SDF-1a in 4-and 7-day Thyroid hormones induce HSC activation I Zvibel et al cultures, with no effect on MCP-1 and TGFb1 (Figure 6a) . Moreover, short-term treatment with T3 also induces expression of TNFa, but not of MCP-1 and TGFb1, as shown after overnight treatment in serum-free medium in 14-day HSC (Figure 6b and c) .
Hyperthyroidism Accelerates Development of Liver Fibrosis and Enhances Activation of HSC In Vivo
We have examined whether thyroid hormones also accelerate activation of HSC, not only in vitro, but also in vivo, using a rat model of TAA-induced fibrosis. Rats have received TAA, or TAA þT3 and TAA þT4, for a period of 3 weeks. Injection of T3 to normal rats for 10 days has been shown to induce liver damage, as determined by increased values for ALT and AST. 17 We have obtained similar results in TAA þT3-treated rats, which have significantly higher ALT than TAA alone, but less ALT and AST than TAA þT4 (Table 1) . Thyroid-stimulating hormone values are lower in the TAA þT3-treated animals and their total T3 is higher than TAA-treated rats, whereas animals receiving T4 have both elevated T3 and free T4 (Table 1) . TAA þT3-and TAA þT4-treated rats have a fibrosis score of 1.6 and 2.8, respectively, compared with 0.8 in rats treated with TAA alone (Table 1) . Higher fibrosis score in TAA þT4-vs TAA þT3-treated rats is not due to increased hepatic damage, as ALT is lower in livers of TAA þT4 than in TAA þT3 (Table 1) . Interestingly, T4 treatment resulted in significantly higher total T3 levels than treatment with T3 (Table 1) . Collagen staining is observed in livers of TAA þT3-and TAA þT4-injected rats, but not in TAA-treated rats (Figure 7a ). There is weak expression Thyroid hormones induce HSC activation I Zvibel et al of aSMA and p75NTR in normal rat liver, yet comparable in its levels to expression of both proteins in livers of rats treated for 3 weeks with TAA ( Figure 7b ). The source of aSMA in the normal liver can be endothelial cells, and also 3-week treatment with TAA is only the beginning of activation of HSC, explaining weak levels of aSMA. Expression of aSMA is increased in a statistically significant manner in the livers of both TAA þT3-and TAA þT4-treated rats, compared with rats receiving TAA (Figure 7c and d) . However, only TAA þT4 treatment, but not TAA þT3, results in statistically higher levels of p75NTR (Figure 7e and f) . We assume that T3 may enhance p75NTR expression at an earlier time, and as we observed that T3 induces a twofold increase and T4 a threefold increase of p75NTR in vitro (Figure 4b ), T4 may also be more potent than T3 in enhancing expression of p75NTR ( Figure 8 ).
DISCUSSION
We have found that thyroid hormones, T3 and T4, are important for activation of primary HSC both in vitro and in vivo. We show that T3 and T4 enhance activation of HSC by three different mechanisms: direct upregulation of aSMA, increased expression of p75NTR and rapid, direct activation of Rho. Activation of Rho is a novel signaling pathway, previously unreported for these hormones. The profibrogenic effect of hyperthyroidism has been reported by several studies from our laboratory, where hyperthyroidism increases and hypothyroidism alleviates liver fibrosis in a TAA rat model, 3 ,4 yet the mechanisms involved are unknown.
We show for the first time that TRa1 expression is regulated by the state of activation of HSC, as strongly activated HSC after 14 days in culture have reduced expression of TRa1, yet the same cells show increased levels of T4 receptor av, as was previously reported. 9 Interestingly, expression of other nuclear hormone receptors involved in lipid metabolism, such as peroxisome proliferator-activated receptors-g, is also reduced in activated HSC, and overexpression of these receptors in activated HSC induces a quiescent phenotype. 21 The main effect of T3 and T4 is upregulation of aSMA expression and accelerated activation of HSC in vitro, and the Thyroid hormones induce HSC activation I Zvibel et al effect of T3 on aSMA is transcriptional and abolished by T3 antagonist 1-850. Similar findings were reported for cardiomyocytes, where T3 enhances aSMA transcription through TRa1 binding to a TRE in the aSMA promoter and T3 addition to TDS induces aSMA in a dose-dependent manner. 17, 18 Recently, it was reported that HSC from p75NTRÀ/À mice failed to activate and did not express aSMA. 10 We show that HSC grown in TDS have low levels of p75NTR and addition of T3 and T4 results in a strong increase in the expression of this receptor, similar to the expression of aSMA under the same conditions. Moreover, T3 and T4 treatment induces transcription of the p75NTR promoter, T3 acting through TRa1 and T4 through cell-surface integrin avb3. The À207/ þ 13 p75NTR promoter is sufficient for the T3-and T4-induced transcriptional effects. The in vitro effects of T3 and T4 are also observed in livers of rats injected for 3 weeks with TAA, where treatment with T3 and T4 increased expression of aSMA in a statistically significant manner. The lack of effect of TAA and T3 on induction of p75NTR in vivo can be explained both by the fact that in vitro experiments show that T4 is more potent than T3 in increasing p75NTR (threefold vs twofold) and by the fact that in vivo administration of T4 resulted in significantly higher serum concentrations of total T3 and free T4, compared to administration of T3.
P75NTR, depending on partnering receptors and on the balance between neurotrophins or proneurotrophins, leads to cell survival or apoptosis. 22 Expression of p75NTR is increased after injury and inflammation, helping recovery from injury, as in remyelination by Schwann cells. 23 TNFa, lipopolysaccharide and transcription factor egr-1, are some of the known regulators of p75NTR transcription. 23 Thyroid hormones may induce transcription of p75NTR directly by binding to TREs in the p75NTR promoter or alternatively, T3 may induce transcription of egr-1, as reported for Schwann cells. 
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In HSC, p75 NTR has a dual role: in the absence of its ligand NGF, it induces cell activation, 23 whereas in the presence of NGF, it induces HSC apoptosis. 21 In the absence of NGF, p75NTR binds Rho inhibitor, Rho-GDI, thus allowing Rho activation. 25 We show that T3 and T4 rapidly and directly induce activation of Rho, with no effect on expression of total Rho. This is a newly described signaling pathway for the two hormones. Rho activation regulates cell adhesion, motility, invasion and metastasis through reorganization of cytoskeleton components. 26 Rho activation is induced by growth factors and extracellular matrix components. 26 Integrin b3 signaling mediates Rho activation, 11 explaining T4 activation of RhoA by binding to integrin avb3. T3 activates Rac1, another GTPase, following association of TRb1 with the p85a subunit of the PI3K. 25 However, in HSC, PI3K is not activated by T3, as shown by unchanged levels of pAkt.
Rho signaling is central to activation of HSC, and inhibition of its downstream signal ROCK by Y-27632, inhibits liver fibrosis and HSC proliferation and activation. 11, 12 Moreover, activation of Rho induces a myofibroblast, aSMAexpressing differentiation program in several cell types. 27, 28 Activation of Rho is followed by activation of ROCK, which phosphorylates non-muscle myosin II, inducing translocation of transcription factors serum response factor and myocardin-related transcriptional activator from the cytoplasm to the nucleus and transcription of aSMA. 28 In accordance with their effect on Rho activation, we show that thyroid hormones also increase phosphorylation of non-muscle myosin II.
In addition to its effect on HSC activation, T3 has also a pro-inflammatory effect on HSC phenotype, enhancing mRNA expression of TNFa and SDF1a, which may also contribute to increasing fibrosis in vivo. Addition of T3 to TDS does not further increase expression of SFD1a in fully activated HSC (14 days in culture), as seen in 4 and 7-day cultures, suggesting that T3 is necessary for regulation of SDF1a expression only during earlier stages of HSC activation. Expression of SDF1a is strongly induced by in vitro activation of HSC. 29 Moreover, SDF1a increases activation of HSC by upregulating aSMA and collagen I and expression levels of both SDF1a and its receptor CXRC4 have been shown to be increased in cirrhotic livers of hepatitis C patients. 30 MCP-1 expression in HSC can be induced by leptin, prostaglandins, TNFa and lipopolysaccharide, 31, 32 and its expression is regulated by different factors, depending on the activation stage of HSC. 33 We have not detected any effect of T3 on modulation of MCP-1 mRNA levels in quiescent, activated or fully activated HSC.
Interestingly, we have observed that treatment of T3 and T4 together with TAA caused liver damage, as shown by high levels of ALT. However, development of liver fibrosis cannot be attributed to apoptosis of damaged hepatocytes, as T3 causes significantly more liver damage than T4, yet T4 is more potent in inducing fibrosis, indicating that fibrosis results from activation of HSC.
In conclusion, thyroid hormones contribute to an activated HSC phenotype by increasing levels of p75NTR, activating Rho and inducing aSMA and thereby participate in accelerated development of liver fibrosis. Exploring these novel mechanisms may increase the range of therapeutic options for treatment of liver fibrosis. Thyroid hormones induce HSC activation I Zvibel et al
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